谷美替尼片, Glumetinib Tablet, Haiyitan, SCC244, 50mg*24 Tablets, Oral Selective MET Inhibitor for MET-Altered Advanced NSCLC: Targeting Exon 14 Skipping & MET Overexpression (IHC 3+)

Gumarontinib tablet
50mg 24pieces/box

Indication:
For the treatment of adult patients with locallyadvanced or metastatic non-small cell lung cancer withMET exon 14 skipping mutations

Gumarontinib is an oral, potent and highly selectivesmall molecule MET inhibitor which global intellectual property rights is owned by Haihe Biopharma. The mechanism of action is to inhibit MET kinase activitypotently and specifically.It has demonstrated clear efficacy benefit in the patientgroup with brain metastases.